KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease.

Susan E Shoaf, Kimberly Sikes

Eur J Pediatr 185(1) 26

PMID41407907
PMCIDPMC12712010
DOI10.1007/s00431-025-06689-2
发表日期2025-12-17
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:非 KM 图;Fig. 3:AI 判定为 other;Fig. 4:非 KM 图。
摘要

摘要

UNLABELLED: Tolvaptan, an oral selective antagonist of the vasopressin V2 receptor, is the only medication for autosomal dominant polycystic kidney disease (ADPKD) with disease-modifying properties in adults at risk of rapid progression. The pharmacokinetics (PK) and pharmacodynamics (PD) of tolvaptan have been well characterized in adults with ADPKD, but data are lacking for adolescents. We assessed prespecified PK/PD endpoints from a randomized clinical trial of tolvaptan in adolescents (ages 12-17 years) with ADPKD (NCT02964273). Dense 24-h PK and PD sampling was conducted in a subgroup of 20 trial participants after a minimum of 1 month on treatment. Endpoints included standard PK parameters and PD endpoints of urine volume, fluid intake, fluid balance, and clearance of sodium, creatinine, and free water. The analysis population (12 tolvaptan; 8 placebo) had well-preserved kidney function. Total daily tolvaptan doses ranged from 22.5-60.0 mg dependent on tolerability. All tolvaptan-treated adolescents had a tolvaptan maximum plasma concentration > 100 ng/mL, urine osmolality in each collection interval of < 215 mOsm/kg, and positive 24-h free water clearance values. In the placebo group, median 12- to 24-h urine osmolality was 507 mOsm/kg, and free water clearance values were close to zero. There was wide interindividual variability in response to tolvaptan, with no correlation between exposure and 24-h urine output or free water clearance. Tolvaptan did not affect sodium excretion. CONCLUSION: Tolvaptan was associated with large increases in free water clearance and urine output. Similar to adult populations, PD responses to tolvaptan varied considerably among adolescent individuals. TRIAL REGISTRATION: EudraCT number: 2016-000187-42 (6 May 2016). CLINICALTRIALS: gov identifier: NCT02964273 (10 November 2016). WHAT IS KNOWN: • The pharmacokinetics and pharmacodynamics of tolvaptan have been well characterized in adults with autosomal dominantpolycystic kidney disease (ADPKD) but its effects have not been studied in adolescents with ADPKD. WHAT IS NEW: • This report presents the pharmacokinetics and pharmacodynamic effects of tolvaptan in adolescents with ADPKD and compares the pharmacodynamic effects to untreated adolescents.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Individual plots of tolvaptan plasma concentrations following tolvaptan split-dose regimens during dense PK/PD sampling. PD, pharmacodynamic; PK, pharmacokinetic; TDD, total daily dose
非 KM Figure
Fig. 2Median urine osmolality by collection interval and dose for tolvaptan- and placebo-treated adolescents during dense PK/PD sampling. PD, pharmacodynamic; PK, pharmacokinetic
非 KM Figure
Fig. 3Median free water clearance by collection interval and dose for tolvaptan- and placebo-treated adolescents during dense PK/PD sampling. PD, pharmacodynamic; PK, pharmacokinetic
非 KM Figure
Fig. 4Mean (SD) fluid intake, urine output and fluid balance for 0 to 24 h for tolvaptan- and placebo-treated adolescents during dense PK/PD sampling . PD, pharmacodynamic; PK, pharmacokinetic; SD, standard deviation
非 KM Figure